Early Prophylaxis Immunologic Challenge (EPIC) Study

2014-10-16 19:33:30 | BioPortfolio

Published on BioPortfolio: 2014-10-16T19:33:30-0400

Clinical Trials [1268 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

The purpose of this study is to evaluate whether rAHF-PFM is effective and safe in the treatment of hemophilia A patients who have not been treated with factor VIII before.

Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Unilateral Knee Replacement

The purpose of this study is to compare the safety and efficacy of continuous infusion versus intermittent bolus infusion employing rAHF-PFM, a recombinant antihemophilic factor manufactur...

Pharmacokinetic Study of Advate Reconstituted in 2 mL Sterile Water for Injection

The purpose of this study is to determine the pharmacokinetics and safety of rAHF-PFM reconstituted in 2 mL sterile water for injection (SWFI) and compare with those of rAHF-PFM reconstitu...

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A patients undergoing surgery.

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

The purpose of this study is to evaluate whether rAHF-PFM is effective and safe in the treatment of children with hemophilia A. The study consists of 2 parts. Part 1 of the study is a phar...

PubMed Articles [22066 Associated PubMed Articles listed on BioPortfolio]

International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.

AFSTYLA (antihemophilic factor [recombinant] single chain) is a novel B-domain truncated recombinant Factor VIII (rFVIII). For AFSTYLA, an approximate 50% discrepancy was observed between results of t...

Lemmings into the sea or back across the bridge? The fate of albumin in nephrotic syndrome.

An intact glomerular filtration barrier is essential for maintaining plasma albumin levels. However, the capacity of the proximal tubule to reabsorb filtered albumin and the subsequent fate of this pr...

2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.

The SH-group at Cys-34 of human serum albumin (HSA) is a unique and accessible functional group that can be exploited for efficient linkage of a maleimide containing cytotoxic drug derivative to album...

Simultaneous Time-concentration Analysis of Soman and VX Adducts to Butyrylcholinesterase and Albumin by LC-MS-MS.

A sensitive method for the purification and determination of two protein adducts, organophosphorus (OP)-BChE and OP-albumin adducts, in a single sample using a simultaneous sample preparation method w...

Binding of sulphonylureas to plasma proteins - A KATP channel perspective.

Sulphonylurea drugs stimulate insulin secretion from pancreatic β-cells primarily by inhibiting ATP sensitive potassium (KATP) channels in the β-cell membrane. The effective sulphonylurea concentrat...

Medical and Biotech [MESH] Definitions

A hereditary deficiency of blood coagulation factor XI (also known as plasma thromboplastin antecedent or PTA or antihemophilic factor C) resulting in a systemic blood-clotting defect called hemophilia C or Rosenthal's syndrome, that may resemble classical hemophilia.

An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.

Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.

A condition in which albumin level in blood (SERUM ALBUMIN) is below the normal range. Hypoalbuminemia may be due to decreased hepatic albumin synthesis, increased albumin catabolism, altered albumin distribution, or albumin loss through the urine (ALBUMINURIA).

Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions.

More From BioPortfolio on "Early Prophylaxis Immunologic Challenge (EPIC) Study"

Quick Search


Searches Linking to this Trial